Immune Efect Of Ulinastatin Combined With Thymosin α₁ In Sepsis Patients

Objective: To investigate the efficacy and immunological function of ulinastatin combined with thymosin α₁ in sepsis patients.Methods: Select the adult (over 18 years old ) who were hospitalized in ICU of Qi Lu Hospital from April 2005 to Janurary 2006 and induced by severly jinjury or infection, comforming to the criteria of sepsis set forth by SCCM and the diagnosis criteria of multiple organ dysfunction syndrome (Marshall, 1995). Thirty patients who were enrolled in this clinical trial were randomly divided into ulinastatin combined with thymosin α₁ treatmeng group (group T) and control group (group C). Besides normal therapy, patients in group T received ulinastatin 300000 units ivdrip. and thymosin α₁ 1.6 mg i.h. twice a day for 3 days, follwing ulinastatin 300000 units ivdrip. and thymosin α₁ 1.6 mg i.h. q.d for 4 days. While patients in group C only received normal therapy. Before treatment and at 3th,8th day after start of treatment, APACHE II and Marshall scores were recorded. The blood concentration of C reactive protein(CRP),procalcitonin(PCT), HLA-DR, CD14⁺,interleukin-6(IL-6) and interleukin-10(IL-10) were determined. Mortality rate and the days patients were hospitalized in ICU were compared at 28 days after treatment between the two groups.Results: The APACHE II and Marshall scores in both groups decreased during the...